While the Human Genome Project was carried out primarily using Sanger sequencing technology, post-genomics studies have utilised Next Generation Sequencing technology – an approach to sequencing nucleic acids that makes generation of gigabases of genetic data possible in a single instrument run.
The Babraham Institute has established the Epigenomics and Transcriptomics Facility, with investment from the Biotechnology and Biological Sciences Research Council (BBSRC) and Medical Research Council (MRC), in partnership with the University of Cambridge’s Centre for Trophoblast Research. The Facility will play a crucial role in the Institute’s research projects on epigenetics, chromatin regulation, cell signalling and immunology, and is also available to external users on a fee-for-service basis.
The Epigenomics and Transcriptomics Facility is equipped with two Illumina Genome Analyzers (GA-IIx) in order to perform Next Generation Sequencing at a high throughput level. The Facility also has an Agilent Bioanalyzer 2100 for DNA sample and library quality control.
Babraham Bioscience Technologies Ltd - Cambridge - United Kingdom